WallStSmart

Merck & Company Inc (MRK)vsPetMed Express Inc (PETS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 39324% more annual revenue ($66.57B vs $168.86M). MRK leads profitability with a 4.8% profit margin vs -17.3%. PETS appears more attractively valued with a PEG of 2.32. PETS earns a higher WallStSmart Score of 43/100 (D).

MRK

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27

PETS

Hold

43

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 6.3Quality: 5.0
Piotroski: 2/9Altman Z: 1.29
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-73.7%)

Margin of Safety

-73.7%

Fair Value

$82.84

Current Price

$143.93

$61.09 premium

UndervaluedFair: $82.84Overvalued
PETSUndervalued (+70.8%)

Margin of Safety

+70.8%

Fair Value

$10.16

Current Price

$1.65

$8.51 discount

UndervaluedFair: $10.16Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$355.10B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

PETS3 strengths · Avg: 9.3/10
EPS GrowthGrowth
266.7%10/10

Earnings expanding 266.7% YoY

Debt/EquityHealth
0.0210/10

Conservative balance sheet, low leverage

Price/BookValuation
1.5x8/10

Reasonable price relative to book value

Areas to Watch

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.5x4/10

Trading at 8.5x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

PETS4 concerns · Avg: 3.0/10
PEG RatioValuation
2.324/10

Expensive relative to growth rate

Market CapQuality
$39.24M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-100.6%2/10

ROE of -100.6% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bull Case : PETS

The strongest argument for PETS centers on EPS Growth, Debt/Equity, Price/Book.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Bear Case : PETS

The primary concerns for PETS are PEG Ratio, Market Cap, Piotroski F-Score.

Key Dynamics to Monitor

MRK profiles as a value stock while PETS is a turnaround play — different risk/reward profiles.

PETS carries more volatility with a beta of 0.79 — expect wider price swings.

MRK is growing revenue faster at 5.1% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Bottom Line

PETS scores higher overall (43/100 vs 36/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

PetMed Express Inc

HEALTHCARE · PHARMACEUTICAL RETAILERS · USA

PetMed Express, Inc., doing business as 1-800-PetMeds, is a pet pharmacy in the United States. The company is headquartered in Delray Beach, Florida.

Want to dig deeper into these stocks?